

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approval for drug production and registration for Nimodipine Oral Solution (10ml:60mg) from the National Medical Products Administration of China (the “NMPA”), being under type 3 chemical drug and regarded as passing the consistency evaluation.

Nimodipine Oral Solution is mainly used in adult patients with subarachnoid hemorrhage (SAH) resulting from ruptured intracranial cystic aneurysms. It improves the patients’ neurological prognosis by reducing the incidence and severity of ischemic nerve injury. As stated in the Company’s announcement dated 19 March 2025, the Group’s Nimodipine bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. This approval of Nimodipine Oral Solution preparation achieves the synergy of integration of bulk pharmaceuticals and preparations, further enriching the Group’s product portfolio in the cardiovascular, cerebrovascular and critical neurological fields.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 8 October 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Meng Guo, Mr. Chow Hing Yeung, Ms. Qu Wanrong and Mr. Wu Hengyao as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.